Aeromics is a startup based in the United States.
Aeromics is a clinical-stage pharmaceutical company developing an intravenously administered aquaporin-4 inhibitor (AER-271) to prevent and treat cerebral edema in patients suffering from severe acute ischemic stroke.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.